

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/N972C0A37F05EN.html>

Date: May 2022

Pages: 35

Price: US\$ 3,500.00 (Single User License)

ID: N972C0A37F05EN

Abstracts

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

According to the recently published report 'Neuropeptide Y Receptor Type 2 - Drugs In Development, 2022'; Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) pipeline Target constitutes close to 5 molecules. Out of which approximately 5 molecules are developed by Companies.

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Neuropeptide Y receptor type 2 (Y2R) is a protein encoded by the NPY2R gene. It is expressed abundantly in the central nervous system. It is also seen in the spleen, liver and intestine. It regulates the release of neurotransmitters by functioning as an autoreceptor and heteroreceptor.

The report 'Neuropeptide Y Receptor Type 2 - Drugs In Development, 2022' outlays comprehensive information on the Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase I, Preclinical and Discovery stages are 1, 3 and 1 respectively. Report covers products from therapy areas Metabolic Disorders and Central Nervous System which include indications Obesity and Epilepsy.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R)

The report reviews Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics and enlists all their major and minor projects

The report assesses Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Overview

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Therapeutics
Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Therapeutics
Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Companies Involved
in Therapeutics Development

Gila Therapeutics Inc

Spark Therapeutics Inc

Takeda Pharmaceutical Co Ltd

XL-protein GmbH

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Drug Profiles

CG-01 - Drug Profile

Product Description

Mechanism Of Action

History of Events

GT-002 - Drug Profile

Product Description

Mechanism Of Action

GT-01 - Drug Profile

Product Description

Mechanism Of Action

History of Events

PYY-1119 - Drug Profile

Product Description

Mechanism Of Action

History of Events

XL-310 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Dormant Products

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Discontinued Products

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Product Development Milestones

Featured News & Press Releases

Feb 11, 2022: CombiGene's CEO gives business development update

Jan 17, 2022: GMP production of CG01 made available for preclinical studies planned to enable first in human study

Dec 16, 2021: CombiGene and Spark Therapeutics plan to expand the clinical development program to include the U.S. as well as Europe

Nov 04, 2021: BioStock: CombiGene are looking for broader opportunities

Oct 22, 2021: CombiGene's scientific founders talk about the quantum leap that the epilepsy project CG01 is about to take

Jul 28, 2021: Patent approved in the U.S. and Russia for CombiGenes gene therapy candidate CG01

Jul 26, 2021: CombiGene initiates GMP production of CG01 for the first-in-human study

Jun 30, 2021: BioStock: CombiGene announces several milestones for CG01

Jun 28, 2021: CombiGene and Neurochase begin work to optimize the administration of CG01

Jun 23, 2021: GMP plasmids released - Ready to start GMP production of CG01

Mar 04, 2021: BioStock: CombiGene advances preclinically and recruits post-doc

Mar 01, 2021: The material from the first large-scale production of CG01 is now released for use in the final parts of the preclinical program

Feb 09, 2021: Interview in BioStock, CombiGene on the International Epilepsy Day and the pharmaceutical authorities' positive response

Feb 03, 2021: Response from the Swedish and UK Pharmaceutical Regulatory Authorities confirms CombiGene's plan for CG01's final preclinical studies

Jan 18, 2021: With the recruitment of Pernilla Fagergren, CombiGene strengthens the company further for the clinical studies in the epilepsy project CG01

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

[Contact Us](#)
[Disclaimer](#)

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indication, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by Gila Therapeutics Inc, 2022

Pipeline by Spark Therapeutics Inc, 2022

Pipeline by Takeda Pharmaceutical Co Ltd, 2022

Pipeline by XL-protein GmbH, 2022

Dormant Projects, 2022

Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indications, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

I would like to order

Product name: Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/N972C0A37F05EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N972C0A37F05EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970